Daniel Chase Harmon, AP | |
4000 Airline Dr Ste 1, Bossier City, LA 71111 | |
(318) 588-5012 | |
Not Available |
Full Name | Daniel Chase Harmon |
---|---|
Gender | Male |
Speciality | Case Manager/care Coordinator |
Location | 4000 Airline Dr Ste 1, Bossier City, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063920361 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101Y00000X | Counselor | (* (Not Available)) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Daniel Chase Harmon, AP 4000 Airline Dr Ste 1, Bossier City, LA 71111-2042 Ph: () - | Daniel Chase Harmon, AP 4000 Airline Dr Ste 1, Bossier City, LA 71111 Ph: (318) 588-5012 |
News Archive
University promotion and tenure criteria and processes should be broadened and made more inclusive to value innovation, entrepreneurship and other forms of scholarly impact, a collaboration led by Oregon State University assert today in a paper published in Science.
Noting that "non-communicable diseases (NCDs) kill four times the number of people in low- and middle-income countries (LMICs) that they do in high-income countries," Benn Grover, a health communications specialist who manages policy for the National Forum for Heart Disease and Stroke Prevention, and Felicia Knaul, an associate professor at Harvard Medical School and director of the Harvard Global Equity Initiative, write in the Huffington Post Blog.
Among mild to moderately obese patients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was associated with a greater likelihood of improved levels of metabolic risk factors such as blood glucose, LDL-cholesterol and systolic blood pressure, according to a study in the June 5 issue of JAMA.
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
› Verified 3 days ago